

Disease	Drug	Company	Therapeutic Role	Type of Drug	Diagnostic Test Specified	Approval Type	Medicare Payment Category
Breast Cancer (BC)	Margenza ( <i>argetuximab-cmkb</i> )	MacroGenics	Third-line for metastatic, HER2+ disease	HER2-neu receptor antagonist	None	Full	Part B
	Phesgo ( <i>ertuzumab, trastuzumab, hyaluronidase-zzxf</i> )	Genentech	Neoadjuvant for HER2+ early BC, adjuvant for high risk HER2+ early BC, and first-line for HER2+ metastatic BC.	Conjugate	HER2 protein overexpression or HER2 gene amplification	Full	Part B
	Trodelvy® ( <i>sacituzumab govitecan-hziy</i> )	Immunomedics	Third-line for triple negative BC	Trop-2-directed antibody and topoisomerase inhibitor conjugate	None	Accelerated	Part B
	Tukysa® ( <i>tucatinib</i> )	Seattle Genetics	Second-line for unresectable or metastatic HER2+ BC	Kinase inhibitor	None	Full	Part D
Cholangiosarcoma	Pemazyre® ( <i>pemigatinib</i> )	Incyte	Second-line for unresectable/metastatic disease with a FGFR2 fusion or rearrangement	Kinase inhibitor	Presence of an FGFR2 fusion or rearrangement	Accelerated	Part D
Diffuse Large B-Cell Lymphoma	Monjuvi® ( <i>tafasitamab-cxix</i> )	MorphoSys/Incyte	Relapsed/refractory patients who are not eligible for ASCT	CD19-directed cytolytic antibody	None	Accelerated	Part B
Epithelioid sarcoma	Tazverik® ( <i>tazemetostat</i> )	Epizyme, Inc.	Patients with metastatic/locally advanced disease ineligible for complete resection	Methyltransferase inhibitor	None	Accelerated	Part D
Follicular Lymphoma (FL)			Third-line for relapsed/refractory EZH2+ positive disease and for FL patients w/o satisfactory treatment options.		Tumors are positive for an EZH2 mutation	Accelerated	
Gastrointestinal Stromal Tumor	Ayvakit ( <i>avapritinib</i> )	Blueprint Medicines Corp.	First-line for unresectable/metastatic PDGFRA mutation-positive disease	Kinase inhibitor	Positive for PDGFRA exon 18 mutation, including PDGFRA D842V mutations	Full	Part D
	Qinlock® ( <i>ripretinib</i> )	Deciphera Pharmaceuticals	4th-line therapy	Kinase inhibitor	None	Full	Part D
Lung Cancer, Non-Small Cell	Gavreto® ( <i>pralsetinib</i> )	Genentech/Blueprint Medicines	Metastatic RET fusion-positive disease	Kinase inhibitor	Presence of a <i>RET</i> gene fusion	Accelerated	Part D
	Retevmo® ( <i>selpercatinib</i> )	Eli Lilly	Metastatic RET fusion-positive disease	Kinase inhibitor	Presence of a <i>RET</i> gene fusion (FDA-approved test for the detection of <i>RET</i> gene fusion not currently available)	Accelerated	Part D
	Tabrecta ( <i>capmatinib</i> )	Novartis	Metastatic disease positive for MET exon 14 skipping	Kinase inhibitor	Presence of a mutation that leads to MET exon 14 skipping.	Accelerated	Part D
Lung Cancer, Small-Cell	Zepzelca ( <i>lurbinectedin</i> )	Jazz Pharmaceuticals	Metastatic small cell disease progressing on/after platinum-based chemo	Alkylating agent	None	Accelerated	Part B
Lymphoma, Mantle Cell	Tecartus ( <i>brexucabtagene autoleucl</i> )	KITE/Gilead	Relapsed/refractory disease	Genetically modified autologous t-cells	None	Accelerated	Part B
Multiple Myeloma	Blenrep ( <i>belantamab mafodotin-blmf</i> )	GlaxoSmithKline	therapy for relapsed/refractory	Antibody-drug Conjugate	None	Accelerated	Part B
	Sarclisa® ( <i>isatuximab-irfc</i> )	Sanofi	3rd-line therapy after lenalidomide and proteasome inhibitor	CD38-directed cytolytic antibody	None	Full	Part B
Myelodysplastic Syndrome	Inqovi® ( <i>decitabine, cedaruzidine</i> )	Taiho Oncology	Myelodysplastic Syndrome (subtypes)	Conjugate of nucleoside metabolic and cytidine deaminase inhibitors	None	Full	Part D
Neuroblastoma	Danyelza® ( <i>namitamab-gqgk</i> )	Y-mAbs Therapeutics	Relapsed/refractory high risk disease in bone marrow which is responsive to prior therapy	GD2-binding antibody	None	Accelerated	Part B
Prostate Cancer	Orgovyx ( <i>relugolix</i> )	Myovant Sciences	Advanced disease	GnRH receptor antagonist	None	Full	Part D
Medullary Thyroid Cancer	Gavreto® ( <i>pralsetinib</i> )	Genentech/Blueprint Medicines	Advanced or metastatic RET-mutant medullary disease	Kinase inhibitor	Presence of RET gene mutation (FDA-approved test not currently available).	Accelerated	Part D
	Retevmo® ( <i>selpercatinib</i> )	Eli Lilly					
Thyroid Cancer	Gavreto® ( <i>pralsetinib</i> )	Genentech/Blueprint Medicines	Advanced or metastatic RET fusion-positive patients who are radio-iodine sensitive	Kinase inhibitor	Presence of a <i>RET</i> gene fusion (FDA-approved test not currently available)	Accelerated	Part D
	Retevmo® ( <i>selpercatinib</i> )	Eli Lilly					